TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2010 - 2026)

TherapeuticsMD's Liabilities from Discontinued Operations history runs 7 years deep, the most recent figure standing at 2667000.0 for Q1 2026.

• Quarterly Liabilities from Discontinued Operations fell 4.24% year-over-year to 2667000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2667000.0 (down 4.24% YoY) and the FY2025 annual result came in at 2667000.0, down 4.1% from the prior year.
• Liabilities from Discontinued Operations was 2667000.0 for Q1 2026 at TherapeuticsMD, roughly flat from 2667000.0 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 25831000.0 in Q4 2022 and bottomed at 1372000.0 in Q2 2023.
• A 5-year average of 4947214.29 and a median of 2783000.0 in 2024 frame the typical range for Liabilities from Discontinued Operations.
• Annual changes were most pronounced in 2023 — Liabilities from Discontinued Operations sank 85.7% — and 2024, when it soared 337.61%.
• TherapeuticsMD's Liabilities from Discontinued Operations stood at 25831000.0 in 2022, then sank by 85.7% to 3694000.0 in 2023, then retreated by 24.72% to 2781000.0 in 2024, then dropped by 4.1% to 2667000.0 in 2025, then changed by 0.0% to 2667000.0 in 2026.
• Business Quant data shows TXMD's Liabilities from Discontinued Operations at 2667000.0 in Q1 2026, 2667000.0 in Q4 2025, and 2667000.0 in Q3 2025.